<p>/PRNewswire/ -- 华辉健康宣布，中国国家药品监督管理局（NMPA）已对其 Libevitug 注射液给予有条件批准，用于治疗成人慢性乙型肝炎病毒感染者（无论是否伴有代偿性肝硬化）。Libevitug 是一种针对乙型肝炎病毒（HBV）和乙型肝炎病毒（HDV）大包膜蛋白 PreS1 域的人单克隆抗体，从而阻止病毒进入肝细胞。作为病毒性肝炎治疗领域的突破性成就，Libevitug 是首个针对病毒性肝炎的抗体治疗，也是中国首个获得批准的 HDV 治疗药物，填补了该领域的重大临床空白。该药物此前已获得中国 NMPA 药品评审中心（CDE）和美国食品药品监督管理局（FDA）的 “突破性疗法认定”。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>世界卫生组织（WHO）和欧洲肝脏研究协会（EASL）的指南一致认为，HDV-HBV 合并感染是慢性病毒性肝炎中最严重的形式，因为其快速进展至肝硬化、肝细胞癌和与肝脏相关的死亡 [1] [2]。HDV 是一种卫星病毒，依赖于 HBV 的包膜蛋白来完成其生命周期，因此仅感染与 HBV 合并感染的个体。慢性 HDV-HBV 合并感染导致肝硬化和肝癌的风险高于 HBV 单一感染，全球 HBV 感染者中约有六分之一的肝硬化和五分之一的肝癌病例与此相关 [3]。</p>
<p>根据 WHO 的数据，HDV 影响近 5%（约 1200 万）慢性 HBV 感染者。鉴于 HDV 感染的严重后果，WHO 在其 2024 年针对慢性乙型肝炎感染者的预防、诊断、护理和治疗指南中建议，对所有 HBsAg 阳性个体进行抗 HDV 抗体的血清学检测，以便扩大 HDV 诊断和护理的获取。在中国，超过 7500 万慢性乙型肝炎患者，有限的 HDV 治疗，加上临床意识不足和检测率低，使得患者没有治疗选择，突显出迫切的医疗需求。</p>
<p>Libevitug 的临床开发始于 2018 年。其关键注册研究（HH003-204）的数据在 2025 年美国肝脏疾病研究协会（AASLD）年会上作为晚间突破报告呈现。这项国际多中心随机对照开放标签的 IIb 期临床试验表明，Libevitug 在主要和次要疗效终点上显著优于对照组，包括联合应答率、病毒学应答、丙氨酸氨基转移酶（ALT）正常化和肝脏硬度改善。Libevitug 还显示出良好的耐受性和令人满意的安全性。在第 48 周，联合应答率达到 44.1%，HDV 病毒学应答率为 60%，ALT 正常化率为 70%，肝脏硬度显著且持续改善。</p>
<p>“Libevitug 展现出卓越的临床疗效，显著改善肝脏硬度，尤其在 HBV/HDV 相关肝硬化患者中效果尤为显著，” 吉林大学第一医院 Libevitug（HH003-204）试验的首席研究员牛俊奇教授表示。“该药物与中国《病毒性肝炎防治行动计划（2025-2030）》的核心目标相一致，旨在提高病毒性肝炎的诊断和治疗率，减少肝癌的发生率和死亡率。我们期待 Libevitug 能有效降低疾病进展至肝癌等严重疾病的风险，推动中国 HDV 诊断和治疗的标准化，推进到 2030 年消除病毒性肝炎作为公共卫生问题的目标，并为全球肝炎控制工作贡献一个科学有效且可及的解决方案。”</p>
<p>Libevitug 的开发源于十多年的科学突破。2012 年，北京国家生物科学研究所（NIBS）由华辉健康的科学创始人李文辉博士领导的团队，首次确定了钠牛磺胆酸共转运多肽（NTCP）作为 HBV 和 HDV 感染的关键受体，这一世界首创的发现解决了数十年来的科学谜团。这一里程碑式的成就为李博士赢得了包括巴鲁克·S·布伦伯格奖、未来科学奖和乙型肝炎研究杰出奖在内的众多荣誉，并为新药开发打开了大门。2015 年，Libevitug 的主导分子通过华辉健康的联合创始人、抗体工程专家隋建华博士与李博士团队的合作开发。“病毒性肝炎的全球负担巨大，” 隋博士表示。“我们很高兴 Libevitug 是该领域首个获得批准的单克隆抗体，有效治疗最严重和进展迅速的慢性病毒性肝炎——HBV 合并感染的 HDV。” 李博士补充道：“我们感谢所有合作伙伴和合作者的宝贵支持。华辉健康和 NIBS 的团队共同努力，完成了从 ‘揭示基本机制’ 到 ‘开发有效药物’ 的全周期生物医学创新，使我们在这一领域处于领先地位，并展示了我们应对人类健康重大挑战的能力和承诺。”</p>
<p>华辉健康首席执行官陈斌博士表示：“Libevitug 的成功获批实现了我们建立一个世界级转化和临床开发平台的承诺，致力于为全球患者提供创新疗法。我们已经建立了一个覆盖整个药物开发过程的综合研发系统，管线从 HDV 和 HBV 扩展到肿瘤学和其他肝病，包含八个核心资产候选药物。展望未来，我们将坚定不移地致力于 ‘源于中国，造福全球’ 的愿景，利用科学保障全球在传染病和肝病方面的医疗健康。”</p>
<p>参考文献：</p>
<p>[1] 世界卫生组织。乙型肝炎 D 型病毒事实表。https://www.who.int/news-room/fact-sheets/detail/hepatitis-d</p>
<p>[2] 欧洲肝脏研究协会。J Hepatol. 2023 年 8 月；79(2) 433-460。</p>
<p>[3] 世界卫生组织。慢性乙型肝炎感染者的预防、诊断、护理和治疗指南。2024 年。</p>
<p><strong>关于慢性 HDV 感染</strong></p>
<p>HDV 是 HBV 的卫星病毒，依赖 HBV 的包膜蛋白完成其生命周期。HDV 通过与 NTCP 结合感染肝细胞，NTCP 是 HBV 共享的受体。HDV 感染仅发生在同时感染 HBV 的个体中。与 HBV 单独感染相比，HBV 和 HDV 的共感染显著增加——通常是翻倍——发展为肝硬化、肝细胞癌（HCC）、需要肝移植和肝相关死亡的风险，使其成为已知的最严重的慢性病毒性肝炎形式。根据世界卫生组织的数据，全球约有 1200 万人感染 HDV，影响近 5% 的所有慢性 HBV 携带者。世界卫生组织建议对所有乙型肝炎表面抗原（HBsAg）阳性个体进行乙型肝炎 D 型病毒的筛查和检测。迄今为止，除了欧洲外，中国和美国尚未批准用于慢性 HDV 感染的药物。</p>
<p><strong>关于 Libevitug (HH-003)</strong></p>
<p>Libevitug 是一种首创的、针对 HBV/HDV 的 PreS1 靶向中和单克隆抗体，由华辉健康发现和开发。该抗体通过特异性阻断病毒 PreS1 区域与宿主 NTCP 受体之间的相互作用，防止病毒进入肝细胞和再感染。Libevitug 的早期开发得到了中国第十三个五年规划下国家重大科技专项新药开发的支持。此前，它已获得中国 CDE、NMPA（2023 年）和美国 FDA（2024 年）对乙型肝炎 D 型病毒的突破性疗法认定（BTD）。</p>
<p><strong>关于华辉健康</strong></p>
<p>华辉健康成立于 2015 年，总部位于北京，是一家致力于开发首创和最佳疗法的生物制药公司，战略重点放在病毒性肝炎、肝病和肿瘤学上。华辉健康秉持以患者为中心的理念和深厚的科学专业知识，遵循创新、诚信、合作和互利的核心原则。华辉健康建立了覆盖整个新药开发过程的综合性、世界级专有平台，确保为全球患者持续提供突破性疗法。</p>
<p>欲了解更多信息，请访问 <strong>www.huahuihealth.com</strong>。</p>
<p>来源：华辉健康有限公司。</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI3Jk5ld3NJdGVtSWQ9Q043MTc5OSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjcwMzE4UFJfTkVXU19VU1BSX19fX19DTjcxNzk5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI3Jk5ld3NJdGVtSWQ9Q043MTc5OSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjcwMzE4UFJfTkVXU19VU1BSX19fX19DTjcxNzk5"/></p>

<p>华辉健康的 Libevitug 注射剂已获得中国国家药品监督管理局的有条件批准，成为治疗慢性乙型肝炎 D 的首个药物。这种人源单克隆抗体靶向 HBV 和 HDV 的 PreS1 区域，阻止病毒进入肝细胞。Libevitug 填补了一个重要的临床空白，尤其是在中国，超过 7500 万人患有慢性乙型肝炎。该药物在临床试验中显示出优越的疗效，综合应答率为 44.1%，病毒学应答率为 60%。它与中国到 2030 年改善肝炎诊断和治疗的目标相一致</p>

<p>, /PRNewswire/ -- Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of the large envelope protein of hepatitis B virus (HBV) and hepatitis D virus (HDV), thereby blocking viral entry into hepatocytes. As a groundbreaking achievement in viral hepatitis therapeutics, Libevitug is a first-in-class antibody therapeutic for viral hepatitis and the first approved treatment for HDV in China, addressing a major clinical gap in this field. The drug previously received &#34;Breakthrough Therapy Designation&#34; from both the Center for Drug Evaluation (CDE) of the China NMPA and the U.S. Food and Drug Administration (FDA).</p>
<div class="lb-trans"><p>/PRNewswire/ -- 华辉健康宣布，中国国家药品监督管理局（NMPA）已对其 Libevitug 注射液给予有条件批准，用于治疗成人慢性乙型肝炎病毒感染者（无论是否伴有代偿性肝硬化）。Libevitug 是一种针对乙型肝炎病毒（HBV）和乙型肝炎病毒（HDV）大包膜蛋白 PreS1 域的人单克隆抗体，从而阻止病毒进入肝细胞。作为病毒性肝炎治疗领域的突破性成就，Libevitug 是首个针对病毒性肝炎的抗体治疗，也是中国首个获得批准的 HDV 治疗药物，填补了该领域的重大临床空白。该药物此前已获得中国 NMPA 药品评审中心（CDE）和美国食品药品监督管理局（FDA）的 “突破性疗法认定”。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>Guidelines from the World Health Organization (WHO) and the European Association for the Study of the Liver (EASL) consistently identify HDV–HBV co-infection as the most severe form of chronic viral hepatitis due to rapid progression towards liver cirrhosis, hepatocellular carcinoma and liver-related death [1] [2]. HDV is a satellite virus that depends on HBV's envelope proteins to complete its life cycle and therefore infects only individuals who are co-infected with HBV. Chronic HDV–HBV co-infection leads to a higher risk of cirrhosis and liver cancer compared to HBV mono-infection, accounting for approximately one in six cases of cirrhosis and one in five cases of liver cancer among people with HBV infection globally [3].</p>
<div class="lb-trans"><p>世界卫生组织（WHO）和欧洲肝脏研究协会（EASL）的指南一致认为，HDV-HBV 合并感染是慢性病毒性肝炎中最严重的形式，因为其快速进展至肝硬化、肝细胞癌和与肝脏相关的死亡 [1] [2]。HDV 是一种卫星病毒，依赖于 HBV 的包膜蛋白来完成其生命周期，因此仅感染与 HBV 合并感染的个体。慢性 HDV-HBV 合并感染导致肝硬化和肝癌的风险高于 HBV 单一感染，全球 HBV 感染者中约有六分之一的肝硬化和五分之一的肝癌病例与此相关 [3]。</p>
</div><p>According to WHO, HDV affects nearly 5% (an estimated 12 million) of people who have a chronic infection with HBV. Given the severe consequences of HDV infection, WHO's 2024 Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection recommend that serological testing for anti-HDV antibodies may be performed for all individuals who are HBsAg positive, as the preferred approach to scale up access to HDV diagnosis and linkage to care. In China, with over 75 million patients living with chronic hepatitis B, limited HDV therapies, compounded by inadequate clinical awareness and low testing rates, have left patients with no treatment options, underscoring a pressing unmet medical need.</p>
<div class="lb-trans"><p>根据 WHO 的数据，HDV 影响近 5%（约 1200 万）慢性 HBV 感染者。鉴于 HDV 感染的严重后果，WHO 在其 2024 年针对慢性乙型肝炎感染者的预防、诊断、护理和治疗指南中建议，对所有 HBsAg 阳性个体进行抗 HDV 抗体的血清学检测，以便扩大 HDV 诊断和护理的获取。在中国，超过 7500 万慢性乙型肝炎患者，有限的 HDV 治疗，加上临床意识不足和检测率低，使得患者没有治疗选择，突显出迫切的医疗需求。</p>
</div><p>Clinical development of Libevitug began in 2018. Data from its pivotal registrational study (HH003-204) were presented as a Late-Breaker at the 2025 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). This international, multicenter, randomized, controlled, open-label Phase IIb clinical trial demonstrated that Libevitug was significantly superior to the control group across primary and secondary efficacy endpoints including combined response rate, virological response, alanine aminotransferase (ALT) normalization, and improvement in liver stiffness. Libevitug also showed favorable tolerability and a satisfactory safety profile. At Week 48, the combined response rate reached 44.1%, along with an HDV virological response rate of 60% and an ALT normalization rate of 70%, and a significant, sustained improvement in liver stiffness.</p>
<div class="lb-trans"><p>Libevitug 的临床开发始于 2018 年。其关键注册研究（HH003-204）的数据在 2025 年美国肝脏疾病研究协会（AASLD）年会上作为晚间突破报告呈现。这项国际多中心随机对照开放标签的 IIb 期临床试验表明，Libevitug 在主要和次要疗效终点上显著优于对照组，包括联合应答率、病毒学应答、丙氨酸氨基转移酶（ALT）正常化和肝脏硬度改善。Libevitug 还显示出良好的耐受性和令人满意的安全性。在第 48 周，联合应答率达到 44.1%，HDV 病毒学应答率为 60%，ALT 正常化率为 70%，肝脏硬度显著且持续改善。</p>
</div><p>&#34;Libevitug demonstrates outstanding clinical efficacy and significantly improves liver stiffness, with particularly remarkable efficacy in patients with HBV/HDV-related cirrhosis,&#34; stated Professor Niu Junqi, principal investigator of the Libevitug (HH003-204) trial from the First Hospital of Jilin University. &#34;This drug aligns with the core objectives of China's Action Plan for the Prevention and Control of Viral Hepatitis (2025–2030), which aims to improve diagnosis and treatment rates for viral hepatitis and reduce the incidence of liver cancer and mortality. We anticipate that Libevitug will help effectively lower the risk of disease progression to advanced severe diseases such as liver cancer, drive the standardization of HDV diagnosis and treatment in China, advance the goal of eliminating viral hepatitis as a public health problem by 2030, and contribute a scientifically robust and accessible solution from China to global hepatitis control efforts.&#34;</p>
<div class="lb-trans"><p>“Libevitug 展现出卓越的临床疗效，显著改善肝脏硬度，尤其在 HBV/HDV 相关肝硬化患者中效果尤为显著，” 吉林大学第一医院 Libevitug（HH003-204）试验的首席研究员牛俊奇教授表示。“该药物与中国《病毒性肝炎防治行动计划（2025-2030）》的核心目标相一致，旨在提高病毒性肝炎的诊断和治疗率，减少肝癌的发生率和死亡率。我们期待 Libevitug 能有效降低疾病进展至肝癌等严重疾病的风险，推动中国 HDV 诊断和治疗的标准化，推进到 2030 年消除病毒性肝炎作为公共卫生问题的目标，并为全球肝炎控制工作贡献一个科学有效且可及的解决方案。”</p>
</div><p>The development of Libevitug stems from a scientific breakthrough over a decade in the making. In 2012, a team at the National Institute of Biological Sciences, Beijing (NIBS) led by Dr. Li Wenhui, scientific founder of Huahui Health, identified the sodium taurocholate cotransporting polypeptide (NTCP) as the critical receptor for HBV and HDV infections—a world-first discovery solving a decades-long scientific mystery. This landmark achievement earned Dr. Li prestigious accolades, including the Baruch S. Blumberg Prize, the Future Science Prize, and the Distinguished Award in Hepatitis B Research, and opened a door for new drug development. In 2015, the lead molecule of Libevitug was developed through a collaboration between Dr. Sui Jianhua, co-founder of Huahui Health and an antibody engineering expert, and Dr. Li's team. &#34;The global burden of viral hepatitis is immense,&#34; stated Dr. Sui. &#34;We are pleased that Libevitug is the first monoclonal antibody approved in this field, effectively treating the most severe and progressive form of chronic viral hepatitis—HDV co-infection with HBV.&#34; Dr. Li added, &#34;We are grateful for the invaluable support from all our partners and collaborators. The teams at Huahui Health and NIBS have worked together to complete the full-cycle of biomedical innovation from 'uncovering fundamental mechanism' to 'developing effective drugs', positioning us at the leading edge of this field and demonstrating our capability and commitment to tackling critical challenges in human health.&#34;</p>
<div class="lb-trans"><p>Libevitug 的开发源于十多年的科学突破。2012 年，北京国家生物科学研究所（NIBS）由华辉健康的科学创始人李文辉博士领导的团队，首次确定了钠牛磺胆酸共转运多肽（NTCP）作为 HBV 和 HDV 感染的关键受体，这一世界首创的发现解决了数十年来的科学谜团。这一里程碑式的成就为李博士赢得了包括巴鲁克·S·布伦伯格奖、未来科学奖和乙型肝炎研究杰出奖在内的众多荣誉，并为新药开发打开了大门。2015 年，Libevitug 的主导分子通过华辉健康的联合创始人、抗体工程专家隋建华博士与李博士团队的合作开发。“病毒性肝炎的全球负担巨大，” 隋博士表示。“我们很高兴 Libevitug 是该领域首个获得批准的单克隆抗体，有效治疗最严重和进展迅速的慢性病毒性肝炎——HBV 合并感染的 HDV。” 李博士补充道：“我们感谢所有合作伙伴和合作者的宝贵支持。华辉健康和 NIBS 的团队共同努力，完成了从 ‘揭示基本机制’ 到 ‘开发有效药物’ 的全周期生物医学创新，使我们在这一领域处于领先地位，并展示了我们应对人类健康重大挑战的能力和承诺。”</p>
</div><p>Dr. Chen Bin, Chief Executive Officer of Huahui Health, stated, &#34;The successful approval of Libevitug fulfills our commitment to building a world-class translational and clinical development platform dedicated to delivering innovative therapies for patients worldwide. We have established an integrated R&amp;D system covering the entire drug development process, with a pipeline expanding from HDV and HBV to oncology and other liver diseases, comprising eight core asset candidates. Going forward, we remain steadfastly committed to our vision of 'Original in China, Benefiting the Globe', leveraging science to safeguard global healthcare in infectious and liver diseases.&#34;</p>
<div class="lb-trans"><p>华辉健康首席执行官陈斌博士表示：“Libevitug 的成功获批实现了我们建立一个世界级转化和临床开发平台的承诺，致力于为全球患者提供创新疗法。我们已经建立了一个覆盖整个药物开发过程的综合研发系统，管线从 HDV 和 HBV 扩展到肿瘤学和其他肝病，包含八个核心资产候选药物。展望未来，我们将坚定不移地致力于 ‘源于中国，造福全球’ 的愿景，利用科学保障全球在传染病和肝病方面的医疗健康。”</p>
</div><p>References:</p>
<div class="lb-trans"><p>参考文献：</p>
</div><p>[1] World Health Organization. Hepatitis D Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/hepatitis-d</p>
<div class="lb-trans"><p>[1] 世界卫生组织。乙型肝炎 D 型病毒事实表。https://www.who.int/news-room/fact-sheets/detail/hepatitis-d</p>
</div><p>[2] European Association for the Study of the Liver. J Hepatol. 2023 Aug; 79(2) 433-460.</p>
<div class="lb-trans"><p>[2] 欧洲肝脏研究协会。J Hepatol. 2023 年 8 月；79(2) 433-460。</p>
</div><p>[3] WHO. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. 2024.</p>
<div class="lb-trans"><p>[3] 世界卫生组织。慢性乙型肝炎感染者的预防、诊断、护理和治疗指南。2024 年。</p>
</div><p><strong>About Chronic HDV Infection</strong></p>
<div class="lb-trans"><p><strong>关于慢性 HDV 感染</strong></p>
</div><p>HDV is a satellite virus of HBV, relying on HBV's envelope proteins to complete its life cycle. HDV infects hepatocytes by binding to NTCP, a receptor shared with HBV. HDV infection occurs only in individuals with concurrent HBV infection. Compared to HBV mono-infection, co-infection with HBV and HDV significantly increases—often doubling—the risk of developing liver cirrhosis, hepatocellular carcinoma (HCC), requiring liver transplantation, and liver-related mortality, making it the most severe known form of chronic viral hepatitis. According to the WHO, approximately 12 million people worldwide are infected with HDV, affecting nearly 5% of all chronic HBV carriers. WHO recommends screening and testing for hepatitis D in all hepatitis B surface antigen (HBsAg)-positive individuals. Until now, aside from Europe, no drugs for chronic HDV infection had been approved in China or the United States.</p>
<div class="lb-trans"><p>HDV 是 HBV 的卫星病毒，依赖 HBV 的包膜蛋白完成其生命周期。HDV 通过与 NTCP 结合感染肝细胞，NTCP 是 HBV 共享的受体。HDV 感染仅发生在同时感染 HBV 的个体中。与 HBV 单独感染相比，HBV 和 HDV 的共感染显著增加——通常是翻倍——发展为肝硬化、肝细胞癌（HCC）、需要肝移植和肝相关死亡的风险，使其成为已知的最严重的慢性病毒性肝炎形式。根据世界卫生组织的数据，全球约有 1200 万人感染 HDV，影响近 5% 的所有慢性 HBV 携带者。世界卫生组织建议对所有乙型肝炎表面抗原（HBsAg）阳性个体进行乙型肝炎 D 型病毒的筛查和检测。迄今为止，除了欧洲外，中国和美国尚未批准用于慢性 HDV 感染的药物。</p>
</div><p><strong>About Libevitug (HH-003)</strong></p>
<div class="lb-trans"><p><strong>关于 Libevitug (HH-003)</strong></p>
</div><p>Libevitug is a first-in-class, PreS1-targeting neutralizing monoclonal antibody against HBV/HDV, discovered and developed by Huahui Health. The antibody functions by specifically blocking the interaction between the viral PreS1 domain and the host NTCP receptor, preventing viral entry into hepatocytes and reinfection. The early-stage development of Libevitug received support from the National Major Science and Technology Project for Significant New Drugs Development under China's 13th Five-Year Plan. Previously, it was granted Breakthrough Therapy Designation (BTD) for Hepatitis D by both China's CDE, NMPA (2023) and the U.S. FDA (2024).</p>
<div class="lb-trans"><p>Libevitug 是一种首创的、针对 HBV/HDV 的 PreS1 靶向中和单克隆抗体，由华辉健康发现和开发。该抗体通过特异性阻断病毒 PreS1 区域与宿主 NTCP 受体之间的相互作用，防止病毒进入肝细胞和再感染。Libevitug 的早期开发得到了中国第十三个五年规划下国家重大科技专项新药开发的支持。此前，它已获得中国 CDE、NMPA（2023 年）和美国 FDA（2024 年）对乙型肝炎 D 型病毒的突破性疗法认定（BTD）。</p>
</div><p><strong>About Huahui Health</strong></p>
<div class="lb-trans"><p><strong>关于华辉健康</strong></p>
</div><p>Founded in Beijing in 2015, Huahui Health is a biopharmaceutical company dedicated to developing first-in-class and best-in-class therapies, with a strategic focus on viral hepatitis, liver diseases, and oncology. Driven by a patient-centric philosophy and profound scientific expertise, Huahui Health operates under the core principles of Innovation, Integrity, Collaboration, and Mutual Benefit. Huahui Health has built integrated, world-class proprietary platforms that cover the entire new drug development process, ensuring sustained delivery of breakthrough therapies for patients worldwide.</p>
<div class="lb-trans"><p>华辉健康成立于 2015 年，总部位于北京，是一家致力于开发首创和最佳疗法的生物制药公司，战略重点放在病毒性肝炎、肝病和肿瘤学上。华辉健康秉持以患者为中心的理念和深厚的科学专业知识，遵循创新、诚信、合作和互利的核心原则。华辉健康建立了覆盖整个新药开发过程的综合性、世界级专有平台，确保为全球患者持续提供突破性疗法。</p>
</div><p>For more information, please visit <strong>www.huahuihealth.com</strong>.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 <strong>www.huahuihealth.com</strong>。</p>
</div><p>SOURCE Huahui Health Ltd.</p>
<div class="lb-trans"><p>来源：华辉健康有限公司。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI3Jk5ld3NJdGVtSWQ9Q043MTc5OSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjcwMzE4UFJfTkVXU19VU1BSX19fX19DTjcxNzk5" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN71799&amp;Transmission_Id=202601270318PR_NEWS_USPR_____CN71799&amp;DateId=20260127"/></p>

Libevitug 在中国获批，成为首个用于治疗丙型肝炎的药物